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The usefulness of IFN-g release assays to monitor the efficacy of anti-tuberculosis (TB) treat-
ment is controversial. Sixty patients affected by culture-confirmed pulmonary TB (M Z 36;
mean age: 39.2 yr; Italians Z 28) were serially tested in a low prevalence setting by means
of QuantiFERON-TB GOLD In-Tube (QFT-IT) at baseline and after a successful six-month therapy
regimen (T6). A sub-group of 40 cases was also tested at 1 and 3 months. Overall, 88.3% of
patients scored a QFT-IT positive result at baseline, with the higher proportion of TB-specific
IFN-g responses in foreign-born patients (pZ 0.04). TB-specific responses were highly variable
over time, the within-person variability being correlated with baseline IFN-g levels (rZ 0.731;
p < 0.001). Overall, 61.6% of cases still tested QFT-IT positive at the completion of therapy.
Average IFN-g levels increased over time, being persistently significantly higher in Italian
patients than in foreign-born cases both at baseline (pZ 0.03) and at T6 (pZ 0.02). Reversion
mainly occurred in patients (26.6%) with baseline IFN-g levels close to the conventional cut-off
value. No indeterminate results were recorded at any study time point.
In conclusion,QFT-ITadds nosignificant information toclinicians for treatmentmonitoringwhen
applied in routine clinical practice in a low prevalence setting. Kinetics of Tcell responses upon TB
treatment and reversion (and conversion) thresholds need to be addressed. Diversity of IFN-g
responses among patients of different geographic origin is an issue to be investigated further.
ª 2010 Elsevier Ltd. All rights reserved.1 706 2649; fax: þ39 081 770 2457.
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The recent development of in vitro innovative blood tests
based on the principle of detecting the release of interferon
(IFN)-g byM. tuberculosis (Mtb)-specific circulating effector
memory T cells has offered an attractive challenge to
tuberculosis (TB) management. Overall, IFN-g release
assays (IGRAs), also referred as T cell based assays, are more
specific than tuberculin skin test (TST), more sensitive in
detecting active TB and correlate better with TB exposure in
immune-competent patients, at least in low prevalence
settings.1,2 Actually there are two commercial IGRAs avail-
able and approved by the US Food and Drug Administration
(FDA): the ELISpot-based assay T-SPOT.TB (Oxford Immu-
notech, Oxford, UK) and the whole blood ELISA-based
format QuantiFERON-TB Gold In-Tube (QFT-IT), provided by
Cellestis (Carniege, Victoria, Australia). Both tests rely on
the use of two Mtb-specific antigens (Ags), that are early
secretory antigen target (ESAT)-6 and culture filtrate
protein (CFP)-10. ESAT-6 and CFP-10 encoding genes have
been mapped to the genomic region of difference (RD)-1,
which is selectively restricted to Mtb while is absent in most
environmental mycobacteria and in all BCG vaccine
strains.1,2 The QFT-IT format also includes a third
TB-specific Ag, that is TB7.7. Since the promising spread of
commercial IGRAs in clinical practice, international guide-
lines and statements have been published worldwide in
order to assess their application and performance inter-
pretation in different patient populations and epidemio-
logical settings.3e6 Although this has lead to the routinely
use of IGRAs for latent TB infection (LTBI) diagnosis and
surveillance of new infection cases, important issues con-
cerning the management of active TB still remain unre-
solved and need to be thoroughly investigated.7e9 First, the
use of IGRAs for diagnostic purposes in this setting is not fully
shared, most observations suggesting the usefulness of
IGRAs to rule out active TB.10e13 Secondly, it is unclear
whether IGRAs can be used as surrogate tools for monitoring
the clinical efficacy of anti-TB treatment. It is thought that
effector memory T cell responses decline upon Ag (bacte-
rial) clearance and are replaced by the pool of central
memory T lymphocytes that mainly produce interleukin (IL)-
2 instead of IFN-g.14,15 By the other, in vitro evidence has
suggested that anti-TB drugs do not exert any inhibitory
effect on IFN-g production within the range of therapeuti-
cally achievable concentrations.16 Recent studies address-
ing the dynamics of specific T cell responses with the use of
IGRAs in patients affected by active TB undergoing specific
treatment have provided quite controversial results. To
date, some studies have shown decreasing or negative
responses, while others have reported increased or persis-
tently positive responses both during and after the
completion of treatment.16e25 Variability of IFN-g responses
was influenced by factors, including assay characteristics,
antigen load and functional diversity of T cell subsets. In
addition, to our knowledge there are limited data on the
usefulness of commercial QFT-IT for anti-TB treatment
monitoring purposes when applied in routine clinical
practice in a low prevalence setting.
To further highlight the clinical relevance of measuring
the T cell response to anti-TB treatment, we evaluatedlongitudinal changes of Mtb-specific IFN-g release by means
of QFT-IT in a selected population of patients affected
by susceptible culture-confirmed TB who successfully
completed a standard six-month therapy regimen in a low
prevalence setting.
Materials and methods
Patients and study design
Sixty patients affected by culture-confirmed pulmonary TB
attending the Respiratory Medicine Divisions of two Italian
tertiary care hospitals (S.Camillo-Forlanini hospital, Rome
and Monaldi hospital, Naples) were prospectively enrolled
between September 2007 and July 2008. Exclusion criteria
were human immunodeficiency virus (HIV) infection, any
drug-resistance, current receipt of immune-suppressive
drugs and previous anti-TB treatment. Diagnostic work-up
included clinical history (previous BCG vaccination),
physical examination, routine blood tests, and standard
chest X-ray. Sputum samples and, in some instances
broncho-alveolar lavage fluids (BALF), were sent for
conventional microbiology, i.e., acid fast bacilli (AFB)-
staining and culture for mycobacteria. High resolution
computed tomography (HRCT) of the thorax was performed
in selected cases. TST was performed by trained hospital
staff through the intradermal inoculation (Mantoux
method) of 5 international units (IU) of purified protein
derivative (Biocine PPD, Chiron, Siena, I). The main trans-
verse diameter of skin induration was measured in milli-
metres (mm) at 72 h. Positive results were recorded
according to the guidelines of the American Thoracic
Society (ATS).26 All patients received a standard six-month
daily combination therapy with isoniazid (I), rifampicin (R),
ethambutol (E) and pyrazinamide (Z) for 2 months followed
by daily IR for additional 4 months. Treatment follow-up
was performed on an out-patient basis by monitoring
sputum microbiology (microscopy and culture) and the
chest X-ray status. No drug-related side effects were
recorded during the whole duration of treatment and no
cases of TB relapse have occurred until nowadays. The local
Ethics Committee approved the study and all patients gave
their oral informed consent.
QFT-IT was serially performed at baseline (T0) and after
6 months (T6) of treatment. In a sub-group of 40 patients,
QFT-IT was repeated also at 1 and 3 months after the start
of therapy (T1 and T3, respectively). QFT-IT performance
and data analysis were realized according to the manu-
factures’ instructions.
Statistical analysis
Univariate analyses were used to compare the clinical and
demographic characteristics among Italian and foreign-born
patients. Quantitative variables were analyzed using
Student t test. Percentages were compared using a Chi
square test or Fisher’s exact test for small numbers.
Comparison between the frequency of QFT-IT and TST
positive results was based on Mc-Nemar test for paired
proportions. Student’s t tests for paired data were used to
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baseline and endpoint. The correlation between baseline
TB-specific IFN-g release and within subject variability of
TB-specific IFN-g release was estimated using the Spearman
rank correlation coefficient. P values were considered as
being statistically significant at or below the alpha value of
0.05. All computations were done with R v. 2.9.1.27
Results
The main demographic and clinical characteristics of the
study patients are reported in Table 1. The study pop-
ulation was composed of 28 Italian patients and 32 foreign-
born cases, 20 of them coming from Romania. Mean stay in
Italy was 6.2  3.5 yr. All cases successfully completed
a six-month regimen of anti-TB treatment, as assessed by
complete symptoms recovery, persistent negative culture
examination and significant improvement of the chest X-ray
status. Sputum conversion on microscopy was achieved in
82% of cases within the first 30 days of therapy. All partic-
ipants were tested by means of QFT-IT at baseline (T0) and
at 6 months (T6) after the start of anti-TB therapy. Table 2
shows the distribution of the proportion of QFT-IT positive
results and the relative analytical data of TB-specific IFN-g
production in the whole population and in the two sub-
groups of patients separately analysed. Overall, QFT-IT
scored a positive result in 88.3% of the total population at
T0, with the higher proportion of TB-specific IFN-g
responses in foreign-born patients (pZ 0.04). The baseline
percentage of QFT-IT positive results also overcame that of
TST positivity in the latter group of patients (p Z 0.04),
while there was no significant difference in test perfor-
mance in the former. More than half of the whole pop-
ulation (66.3%) still scored a QFT-IT positive result at T6.
Mean concentrations of TB-specific IFN-g release increased
along with time (mean fold increase of 5.5, p Z ns), being
persistently significantly higher in Italian patients both at
baseline and at the completion of treatment. TheseTable 1 Demographics and clinical characteristics of the study
Parameter Total
Patients, n (%) 60
Males, n (%) 36 (60)
Age b, yr 39.2  14.3 (1.8)
36 [17e74]
TSTþ, n (%) 45 (75.0)
BCG vaccination, n (%) 26 (43.3)
AFBþ, n (%) 39 (65)
AFB score:
1, n (%) 6 (15.3)
2, n (%) 9 (23)
3, n (%) 20 (51.2)
4, n (%) 4 (10.2)
Cavitary TB, n (%) 24 (40)
Bilateral TB, n (%) 25 (41.6)
Statistics: Chi square or Fisher exact test in case of qualitative varia
significant.
a Countries of origin other than Romania included Columbia, Costa R
Philippines and Ukraine.
b Data are expressed as mean  SD (SEM); median [range].findings were not correlated with any disease associated
factor, including sputum bacterial load, X-ray evidence of
cavitation or disease extension (monolateral vs bilateral),
or sputum conversion time (less or more than 30 days). No
differences in the absolute count of peripheral lymphocytes
at baseline and at T6 were recorded comparing QFT-IT
positive and QFT-IT negative patients. No indeterminate
results were scored at any study time point. Table 3
summarizes within-person dichotomous changes in QFT-IT
status. As shown, QFT-IT reversion was scored in less than
one third of the whole population. Reversions mainly
occurred in patients with low baseline IFN-g levels (i.e.,
close to the cut-off value) and was associated with cavitary
TB (p Z 0.041). Conversely, the majority of cases had
unchanged qualitative QFT-IT responses.
To address the dynamics of IFN-g release along with
treatment, QFT-IT was further performed after 1 and 3
months of therapy in a sub-group of 40 patients. To date,
longitudinal changes in IFN-g production in 40 patients
respectively tested QFT-IT negative (n Z 6) and QFT-IT
positive (n Z 34) at baseline. Three out 6 QFT-IT negative
patients scored a transient positive response at T1 or T3.
Definitive QFT-IT conversion to a positive response (1.2
IU/mL) was achieved only in one case at the end of therapy
(T6). Monitoring of IFN-g responses among QFT-IT positive
patients provided highly variable results over time - some
individuals showed increases of IFN-g levels, while some
others showed decreases or no variations. Overall, the
ability to mount stronger, persistent or weaker IFN-g
responses over time was not associated with age, sex,
origin, or with any disease related feature. Conversely,
within-person variability was positively correlated with
baseline IFN-g production (r Z 0.731; p < 0.001).
Discussion
The present longitudinal study was designed to evaluate
the impact of anti-TB treatment on specific IFN-g responsespopulation.
Italians Foreign-borna p
28 (46.6) 32 (53.3) e
14 (50) 22 (68.7) ns
42.7  17.2 (3.2) 36  10.5 (1.8) ns
41 [17e74] 33.5 [20e61]
23 (82.1) 22 (65.6) ns
0 (0) 26 (81.2) e
15 (57.1) 24 (71.8) ns
3 (18.7) 3 (13) ns
5 (31.2) 4 (17.3)
8 (50) 12 (52.1)
0 (0) 4 (17.3)
10 (35.7) 14 (43.7) ns
10 (35.7) 15 (46.8) ns
bles; unpaired t-test in case of quantitative variables; ns Z not
ica, Croatia, Ethiopia, India, Moldavia, Morocco, Pakistan, Peru,
Table 2 Distribution of analytical QFT-IT positive results at baseline (T0) and at 6 months (T6) after start of treatment.
Parameter Total Italians Foreign-born p
Tested cases at T0, n 60 28 32 e
QFT-ITþ, n (%) 53 (88.3) 22 (78.5) 31 (96.8) 0.04
IFN-g production [IU/mL] a 4.77  6.6 (0.9) 7.36  8.7 (1.9) 2.93  3.8 (0.7) 0.03
2.2 [0.36e28.1] 2.4 [0.42e28.1] 1.9 [0.36e17.6]
Blood lymphocytes/mm3 a 1598  465 (60) 1609  477 (90) 1587  462 (81) ns
1565 [759e2845] 1588 [759e2442] 1532 [952e2845]
Tested cases at T6, n 60 28 32
QFT-ITþ, n (%) 38 (63.3) 17 (60.7) 21 (65.6) ns
IFN-g production [IU/mL] a 7.29  8.25 (1.3) 11.0  9.6 (2.3) 4.3  5.6 (1.2) 0.02
4.2 [0.42e33.3] 9.9 [0.82e33.3] 1.6[0.4e24.2]
Blood lymphocytes/mm3 a 1834  582 (75) 1781  614 (116) 1881  559 (98) ns
1786 [668e3313] 1760 [668e3260] 1825 [1050e3313]
Statistical test: Chi square test in case of qualitative variables; unpaired t-test in case of quantitative variables; ns Z not significant.
a Data are expressed as mean  SD (SEM); median [range].
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confirmed pulmonary TB who successfully completed
a standard therapy regimen. Although increasing efforts
have been focused on IGRAs use in clinical monitoring of
anti-TB therapy,16e25 to our knowledge only a limited
number of studies has addressed the usefulness of
commercial last generation ELISA-based QFT-IT in this
scenario. Despite our study was realized in a low preva-
lence area, ethnicity of the study population was quite
heterogeneous as it was composed both of Italian patients
and of foreign-born cases mainly coming from high TB
burden countries. This is an important issue as differences
in QFT-IT performance were recorded when patients were
separately analysed. Baseline QFT-IT assessment had
a sensitivity of 88.3%, which significantly ranged from 78.5%
in Italian patients to 96.8% among those foreign-born.
Overall, sensitivity of commercial ELISA-based IGRAs varies
across studies ranging from 64% with QFT-Gold (the
predecessor of QFT-IT)23 to 95% by means of QFT-IT,25 the
assay characteristics, local epidemiology and disease
features accounting for these differences.
Unexpectedly, baseline levels of IFN-g were significantly
higher in Italian cases than in foreign-born patients. It is
unclear whether the intensity of IGRA responses may be
detecting proxy recent TB exposure. Unfortunately, this
was not so easy to be addressed in our setting. This finding
was even more surprising as the majority of foreign-born
patients were living in Italy for a mean time of more than 5
years suggesting no substantial differences at least in
environmental TB exposure in comparison with resident
patients. Recent observations suggest that quantitativeTable 3 Monitoring of QFT-IT status at baseline and at 6 month
QFT-IT status Total (n Z 60) Italia
Positive > positive 37 (61.6) 16 (5
Negative > negative 6 (10) 5 (1
Positive > negative 16 (26.6) 6 (2
Negative > positive 1 (1.6) 1 (3
Statistics: Fisher exact test.
a Data are expressed as n (%).IFN-g responses are correlated with disease activity.28e30
This was not the case in our setting, while additional
factors including the influence of prior TB exposure in the
country of origin,31 immunological and genetic factors, and
strain differences cannot be excluded as well.
Although QFT-IT is a robust and highly reproducible
assay,32 we found that TB-specific responses were highly
variable over time, the within-person variability being
correlated with baseline IFN-g levels. Intra-individual
variability has been reported across different studies,
ranging from 16 to 80%.33 It is widely thought that this is an
issue of concern having implications for the interpretation
of results close to the cut-off point and the definition of
test conversion and reversion in serial testing,34,35 as the
optimal threshold to distinguish these events from non
specific variations is actually not known. Recently, Veer-
apathran et al. have recommended a 30% increase in the
cut-off level in the response as a true conversion looking at
active TB patients.36 In addition, Pai et al. have found that
the rate of QFT conversions may significantly change upon
different-cut-off values when looking at LTBI cases.37,38
In agreement with previous observations in cured TB
cases,25,39e41 a consistent proportion of patients (66.3%)
still scored a positive QFT-IT response, which occurred
along with an increase of IFN-g levels, at the completion of
therapy. Conversely, Sauzzullo et al. have found that QFT-
IT positive responses became negative in 27 out of 38 cured
patients while disease resolution was not achieved in 5 out
11 patients who had a persistent IFN-g response.16 There is
evidence that cured TB patients can retain strong ESAT-6
responses for several years after the completion ofs after start of treatment.a
ns (n Z 28) Foreign-born (n Z 32) p
7) 21 (65.6) ns
7.8) 1 (3)
1.4) 10 (31.2)
.5) 0 (0)
QFT-IT monitoring of anti-TB therapy 1555therapy.18 Chee et al. first proposed that differential T cell
responses to ESAT-6 and CFP-10 may suggest different
function properties. To date, T cell responses to ESAT-6 may
persist as a scar of previously treated or quiescent infec-
tion, whereas those to CFP-10 may be indicative of active
disease as decrease over time upon successful treatment.42
By this point of view, QFT-IT, which represents the latest
improvement of the previous in plate format, is critically of
limited usefulness as all TB antigens are tested simulta-
neously in a single tube. In our setting, 63% of 15 patients
randomly re-tested after further 6 months from the
completion of therapy still scored a QFT-IT response in the
absence of any clinical sign of TB relapse (mean IFN-g
levels  SD: 7.11  7.5 IU/mL; range: 0.4e20.7). Finally,
reversion to a negative QFT-IT response was achieved in
about one third of the study population (26.6%). In agree-
ment with previous observations37,39 most of cases who
became negative on QFT-IT had baseline IFN-g levels close
to the conventional cut-off point. Conversion to a positive
QFT-IT result at T6 was not a concern in our series as it was
recorded in only one patient (1.6%).
In conclusion, our results suggest that QFT-IT adds no
significant information to clinicians for treatment moni-
toring as long lasting IFN-g responses may persist despite
the infection has been successfully cured.
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